Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations

David M. Hyman, Ben Tran, Luis Paz-Ares, Jean Pascal MacHiels, Jan H. Schellens, Philippe L. Bedard, Mario Campone, Philippe A. Cassier, John Sarantopoulos, Ulka Vaishampayan, Rashmi Chugh, Amit Mahipal, A. Craig Lockhart, Cristiana Sessa, Thomas Zander, Matthew Ng, Giuseppe Curigliano, Jennifer Bendiske, Xueying Chen, Somesh ChoudhuryDiana Graus-Porta, Nancy Lewis, Jose Manuel Perez Garcia, María José De Miguel-Luken

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations'. Together they form a unique fingerprint.

Medicine & Life Sciences